SCHEMBL737402

SCHEMBL737402

COc1ccc(-c2cc(=O)c3c(O)c4c(cc3o2)OCO4)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.63
MEN1 O00255 6/20 0.63
KMT2A Q03164 6/20 0.63
FLT3 P36888 5/20 0.63
NPC1 O15118 5/20 0.63
RAB9A P51151 4/20 0.63
POLB P06746 3/20 0.63
NFKB1 P19838 2/20 0.63
NFKB2 Q00653 2/20 0.63
RELA Q04206 2/20 0.63
KIT P10721 1/20 0.63
OPRD1 P41143 1/20 0.63
MAOB P27338 2/20 0.61
CYP19A1 P11511 1/20 0.61
ALDH1A1 P00352 4/20 0.59
CYP3A4 P08684 4/20 0.59
CYP2C9 P11712 3/20 0.59
CYP2C19 P33261 3/20 0.59
IP6K2 Q9UHH9 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL739211 0.87 KMT2A (0.61) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL971282 0.84 ABCB1 (0.61) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL737399 0.82 ACHE (0.53) MAOBMAOAABCB1
SCHEMBL16525544 0.80 ALDH1A1 (0.67) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL6242511 0.79 KMT2A (0.81) MAPTMEN1KMT2AFLT3NPC1
Ladanein SCHEMBL737069 0.78 FLT3 (0.81) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL16521507 0.78 MAPT (0.71) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL28592818 0.78 MAPT (0.74) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL1976134 0.78 FLT3 (0.76) MAPTMEN1KMT2AFLT3NPC1
SCHEMBL10001079 0.78 MAPT (0.67) MAPTMEN1KMT2AFLT3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US disclosed
EP-1556031-A4 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES INC (US) 2009-03-25 EP disclosed
US-20060142211-A1 Chromones and chromone derivatives and uses thereof TAIWANJ PHARMACEUTICALS CO., LTD. (TW) 2006-06-29 US disclosed
EP-1556031-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF Jenken Bioscience, Inc. (US) 2005-07-27 EP disclosed
WO-2004037193-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES, INC. (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142211-A1 Chromones and chromone derivatives and uses thereof PROC, HMGB1, PYCARD MAPT 3414/4885MEN1 1195/4885KMT2A 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.